Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Asset Writedowns and Impairment (2023 - 2024)

Historic Asset Writedowns and Impairment for Kezar Life Sciences (KZR) over the last 2 years, with Q2 2024 value amounting to $1.5 million.

  • Kezar Life Sciences' Asset Writedowns and Impairment changed N/A to $1.5 million in Q2 2024 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year decrease of 6428.57%. This contributed to the annual value of $1.5 million for FY2024, which is 4262.96% down from last year.
  • As of Q2 2024, Kezar Life Sciences' Asset Writedowns and Impairment stood at $1.5 million.
  • Over the past 5 years, Kezar Life Sciences' Asset Writedowns and Impairment peaked at $2.7 million during Q4 2023, and registered a low of $1.5 million during Q2 2024.